Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Bloomage BioTechnology Corporation Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963) VOLUNTARY ANNOUNCEMENT

This announcement is voluntarily made by Bloomage BioTechnology Corporation Limited (the "Company", together with its subsidiaries, the "Group") to provide the shareholders and potential investors of the Company with updates about the Group's business.
As disclosed in the Company's interim results announcement for the six months ended 30 June 2014, the Group will, with focus on its own industry, brand and technological advantages, continue to use HA new products and other competitive new raw materials to constantly expand the sales channels, strengthen strategic cooperation with key customers in the areas of cosmetics, pharmaceuticals and health food to consolidate its scale and increase its market shares. The directors of the Company consider that the Group's results for the first half of the year have met their expectations.
The Group's new industrial park in Jinan City, Shandong Province has been gradually put into operation in the second half of the year and satisfactory production progress has been made. It is expected that the Group's production capacity will gradually increase from existing approximately 60 tonnes to over 200 tonnes in the near future. The directors of the Company are of the opinion that following the production capacity expansion and technology upgrade, the Group will be more favorable in strategic market competition in areas such as product quality, technology standards and capacity provision, which will facilitate the long-term stable development of the Group.
- 1 -
With its existing operational strategies and business model, the Group will continue to explore new forms of business and actively plan for strategic cooperation with other companies and brands in order to expand the width of its whole marketing chain and bring stronger growth impetus for the business of the Group. If the above plans shall be materialised, the Company will publish an announcement in relation to such matters in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. In view of the above, the directors of the Company are of the view that the Group's results for the full year are expected to meet their expectations.
Hong Kong, 1 September 2014
By order of the Board

Bloomage BioTechnology Corporation Limited ZHAO YAN

Chairman

As at the date of this announcement, the executive directors of the Company are Ms. Zhao Yan, Mr. Jin Xuekun, Ms. Liu Aihua and Ms. Wang Aihua; the non-executive director is Mr. Guo Jiajun; the independent non-executive directors are Ms. Zhan Lili, Mr. Hai Wen and Mr. Li Junhong.

- 2 -

distributed by